AstraZeneca wagers on $500M buyout, plucks PhIII drug for Alexion’s rare disease pipeline — and jumps straight into risky field

Amber Tong

Marc Dunoyer has unveiled his first buyout since taking over at Alexion — one that his predecessors have lassoed in before a $39 billion merger made …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

AstraZeneca wagers on $500M buyout, plucks PhIII drug for Alexion’s rare disease pipeline — and jumps straight into risky field

Amber Tong

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

US warns drugmakers against misrepresenting cost of imported products

Merus’ Phase 2 overall survival data reach ‘home run’ scenario — analyst

Geoffrey Porges exits Schrödinger with CFO swap; A new board seat for AstraZeneca's Pascal Soriot

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

As­traZeneca wa­gers on $500M buy­out, plucks PhI­II drug for Alex­ion’s rare dis­ease pipeline — and jumps straight in­to risky field

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

AstraZeneca wagers on $500M buyout, plucks PhIII drug for Alexion’s rare disease pipeline — and jumps straight into risky field